Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2000, p. 125-132, Vol. 38, No. 1
Institute of Biotechnology, University of
Helsinki, 00014 Helsinki,1 and
Department of Otorhinolaryngology, Helsinki University
Central Hospital, 00290 Helsinki,2 Finland
Received 26 July 1999/Returned for modification 9 September
1999/Accepted 22 September 1999
The multiplex PCR method for the detection of Alloiococcus
otitidis, Haemophilus influenzae, Moraxella
catarrhalis, and Streptococcus pneumoniae (P. H. Hendolin, A. Markkanen, J. Ylikoski, and J. J. Wahlfors, J. Clin. Microbiol. 35:2854-2858, 1997) in middle ear effusions (MEEs)
was modified to be better suited for clinical use. To detect
false-negative results, an internal amplification was added to the
reaction, and to prevent carryover contamination, the
dUTP-uracil-N-glycosidase system was incorporated into the procedure.
Labor was minimized by using the heat-activatable AmpliTaq Gold
polymerase in order to circumvent manual hot start and by detecting the
amplification products on an automated sequencer. The performance of
the improved protocol was verified with MEEs from patients with otitis
media with effusion. In addition, a ligase detection reaction (LDR) was
developed for confirmation of the PCR products. The modifications
increased the reliability of the protocol and the hands-off time
significantly. However, when two DNA extraction protocols were
compared, gram-negative bacteria were detected more often in
phenol-treated MEEs (94 versus 46%; P < 0.001), and
gram-positive bacteria were detected more often in MEEs dissolved in
sodium dodecyl sulfate-NaOH-chaotropic salt (83 versus 27%;
P < 0.001). The LDR was found to be 100% specific.
In all, the results demonstrate the feasibility of the rapid (7-h)
multiplex PCR method for routine laboratory use.
0095-1137/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Clinically Applicable Multiplex PCR for Four Middle
Ear Pathogens
*
Corresponding author. Mailing address: Institute of
Biotechnology, University of Helsinki, P.O. Box 56, Viikinkaari 9, 00014 Helsinki, Finland. Phone: 358-9-708 59 411. Fax: 358-9-708 59 416. E-mail: Panu.Hendolin{at}Helsinki.fi.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»